Healthcare provider profile · identity verified

Carl A Sather, MD

Internal Medicine · MAHOMET, IL · NPI 1174733034

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	369	119
Levothyroxine Sodium	Levothyroxine Sodium	238	67
Amlodipine Besylate	Amlodipine Besylate	215	65
Lisinopril	Lisinopril	215	70
Metoprolol Succinate	Metoprolol Succinate	191	61
Gabapentin	Gabapentin	185	62
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	157	32
Omeprazole	Omeprazole	151	49
Hydrochlorothiazide	Hydrochlorothiazide	148	45
Losartan Potassium	Losartan Potassium	141	40
Simvastatin	Simvastatin	141	37
Tamsulosin Hcl	Tamsulosin Hcl	136	40
Rosuvastatin Calcium	Rosuvastatin Calcium	129	40
Furosemide	Furosemide	122	31
Albuterol Sulfate Hfa	Albuterol Sulfate	107	48
Pantoprazole Sodium	Pantoprazole Sodium	102	39
Carvedilol	Carvedilol	93	31
Trazodone Hcl	Trazodone Hcl	86	26
Jardiance	Empagliflozin	83	20
Eliquis	Apixaban	78	22
Sertraline Hcl	Sertraline Hcl	77	21
Allopurinol	Allopurinol	74	21
Fluoxetine Hcl	Fluoxetine Hcl	73	16
Duloxetine Hcl	Duloxetine Hcl	72	21
Warfarin Sodium	Warfarin Sodium	72	19
Clopidogrel	Clopidogrel Bisulfate	70	25
Alprazolam	Alprazolam	69	19
Metformin Hcl	Metformin Hcl	66	21
Pravastatin Sodium	Pravastatin Sodium	65	21
Pregabalin	Pregabalin	63	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	58	21
Baclofen	Baclofen	55	19
Montelukast Sodium	Montelukast Sodium	53	14
Finasteride	Finasteride	52	17
Donepezil Hcl	Donepezil Hcl	51	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	51	17
Metoprolol Tartrate	Metoprolol Tartrate	46	16
Clonazepam	Clonazepam	45	suppressed
Fluticasone Propionate	Fluticasone Propionate	45	20
Tizanidine Hcl	Tizanidine Hcl	44	21
Repaglinide	Repaglinide	43	14
Ozempic	Semaglutide	41	12
Diazepam	Diazepam	40	suppressed
Glipizide Er	Glipizide	40	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	37	12
Famotidine	Famotidine	37	suppressed
Metformin Hcl Er	Metformin Hcl	36	18
Potassium Chloride	Potassium Chloride	36	15
Tramadol Hcl	Tramadol Hcl	36	11
Diclofenac Sodium	Diclofenac Sodium	35	12
Oxycodone Hcl	Oxycodone Hcl	35	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	35	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	suppressed
Lorazepam	Lorazepam	29	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	29	suppressed
Glimepiride	Glimepiride	28	11
Topiramate	Topiramate	28	suppressed
Bupropion Xl	Bupropion Hcl	26	11
Terazosin Hcl	Terazosin Hcl	26	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Loperamide	Loperamide Hcl	25	suppressed
Fentanyl	Fentanyl	24	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	24	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	23	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Spiriva Respimat	Tiotropium Bromide	23	suppressed
Spironolactone	Spironolactone	23	11
Torsemide	Torsemide	23	suppressed
Meloxicam	Meloxicam	22	suppressed
Ondansetron Odt	Ondansetron	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Linzess	Linaclotide	21	suppressed
Trulicity	Dulaglutide	21	suppressed
Glipizide	Glipizide	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	19	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Prednisone	Prednisone	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	17	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	17	15
Ezetimibe	Ezetimibe	17	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Nitroglycerin	Nitroglycerin	17	14
Alfuzosin Hcl Er	Alfuzosin Hcl	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Rybelsus	Semaglutide	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Entresto	Sacubitril/Valsartan	14	suppressed
Mupirocin	Mupirocin	14	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	14	suppressed
Oxycontin	Oxycodone Hcl	14	suppressed
Syeda	Ethinyl Estradiol/Drospirenone	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Lamotrigine Er	Lamotrigine	12	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Digoxin	Digoxin	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Lyrica	Pregabalin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error